唑来膦酸治疗原发性骨质疏松的临床疗效

Clinical efficacy of zoledronic acid in treatment of primary osteoporosis

目的研究唑来膦酸治疗原发性骨质疏松的临床疗效。方法 76例原发性骨质疏松患者采用唑来膦酸静脉滴注治疗,比较治疗前后骨密度、肾功能、血钙水平、骨转换标志物及不良反应。结果与治疗前相比,唑来膦酸治疗后患者腰椎骨密度值增加(P<0.01),血清Ⅰ型胶原氨基端肽原(PINP)和Ⅰ型胶原羧基端肽β特殊序列(β-CTX)水平均降低(P<0.01),而股骨颈骨密度值、血钙和血肌酐水平无统计学差异(P>0.05)。唑来膦酸治疗的主要不良反应为发热和肌骨痛,经对症治疗后好转。结论唑来膦酸可明显降低骨转换率,抑制骨吸收,提高骨密度,对原发性骨质疏松具有较好的疗效,不良反应少。

Objective To investigate the clinical efficacy of zoledronic acid in the treatment of primary osteoporosis.Methods A total of 76 patients with primary osteoporosis was intravenously infused with zoledronic acid 5 mg.The bone mineral density（BMD）,renal function,serum levels of calcium and creatinine,markers of bone turnover and adverse effects were compared before and after treatment.Results Compared with before,BMD of lumbar vertebrae was increased（P〈0.01）,serum levels of PINP and β-CTX were decreased（P〈0.01）,while BMD of femoral neck,serum levels of calcium and creatinine were not significantly changed after treatment（P〉0.05）.The main adverse effects were fever and musculoskeletal pain,which were effectively improved after symptomatic treatment.Conclusion Zoledronic acid is safe and effective in reducing the rate of bone turnover,inhibiting the bone resorption and increasing BMD.